Ustekinumab for Crohn's disease: a nationwide real-life observational cohort study (ICC case series)

被引：0
|
作者：
Biemans, V. [1 ,2 ]
van der Meulen-de Jong, A. [3 ]
van der Woude, C. [4 ]
de Boer, N. [5 ]
Dijkstra, G. [6 ]
Oldenburg, B. [7 ]
Ponsioen, C. [8 ]
Maljaars, P. [3 ]
Haans, J. [2 ]
Pierik, M. [2 ]
Hoentjen, F. [9 ]
机构：
[1] Radboudumc, Nijmegen, Netherlands
[2] MUMC, Maastricht, Netherlands
[3] LUMC, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[4] Erasmus MC, Rotterdam, Netherlands
[5] Vrije Univ Amsterdam, Med Ctr, Inst Educ, Dept Gastroenterol & Hepatol, Room J393, Amsterdam, Netherlands
[6] Univ Med Ctr Groningen, Groningen, Netherlands
[7] Univ Med Ctr Utrecht, Utrecht, Netherlands
[8] AMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[9] Radboudumc, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP036
引用
收藏
页码：S55 / S56
页数：3
相关论文
共 50 条
  • [31] Biosimilar infliximab in real-life Crohn's disease's anti-TNFalfa naive patients: a comparative observational cohort study (SIMRECRO study)
    Carvalho Lourenco, L.
    Anapaz, V.
    Oliveira, A. M.
    Branco, J.
    Cardoso, M.
    Graca Rodrigues, C.
    Santos, L.
    Horta, D.
    Martins, A.
    Reis, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S259 - S259
  • [32] DRUG SURVIVAL OF VEDOLIZUMAB-TREATED INFLAMMATORY BOWEL DISEASE PATIENTS IN A NATIONWIDE OBSERVATIONAL COHORT STUDY: ICC CASE SERIES
    Biemans, Vince
    Van der Woude, Christien Janneke
    Dijkstra, Gerard
    Van der Meulen, Andrea
    Oldenburg, Bas
    de Boer, Nanne
    Ponsioen, Cyriel
    de Vries, Annemarie C.
    Haans, Jeoffrey
    Pierik, Marie
    Hoentjen, Frank
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S838 - S838
  • [33] Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case series
    Biemans, V.
    van der Woude, C.
    Dijkstra, G.
    van der Meulen-de Jong, A.
    Oldenburg, B.
    de Boer, N.
    Ponsioen, C.
    de Vries, A.
    Haans, J.
    Pierik, M.
    Hoentjen, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S405 - S405
  • [34] EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN REAL-LIFE STUDIES: A META-ANALYSIS
    Macaluso, F. S.
    Maida, M.
    Ventimiglia, M.
    Cottone, M.
    Orlando, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2020, 52 : S129 - S129
  • [35] USTEKINUMAB INDUCES LIMITED MUCOSAL HEALING AFTER 6 MONTHS IN A REAL-LIFE, PROSPECTIVE COHORT OF PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Verstockt, Bram
    Noman, Maja
    Aerden, Isolde
    Peeters, Miet
    Brouwers, Els
    Ballet, Vera
    Vandersmissen, Liesbeth
    Van Assche, Gert A.
    Gils, Ann
    Vermeire, Severine
    Ferrante, Marc
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S836 - S836
  • [36] Ustekinumab in bio-naive and bio-failure Crohn's disease patients: Results from a "real-life" monocentric cohort
    Monin, L.
    Dubois, S.
    Reenaers, C.
    Van Kemseke, C.
    Latour, P.
    Van Daele, D.
    Vieujean, S.
    Seidel, L.
    Louis, E.
    [J]. DIGESTIVE AND LIVER DISEASE, 2021, 53 (01) : 72 - 78
  • [37] Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn's disease
    Verstockt, B.
    Noman, M.
    Aerden, I.
    Peeters, M.
    Brouwers, E.
    Ballet, V.
    Vandersmissen, L.
    Van Assche, G.
    Gils, A.
    Vermeire, S.
    Ferrante, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S467 - S467
  • [38] TWO YEAR EXPERIENCE WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF THE ICC CASE SERIES, A NATIONWIDE PROSPECTIVE OBSERVATIONAL COHORT STUDY
    Biemans, Vince
    Van der Woude, Christien Janneke
    Dijkstra, Gerard
    Meulen-de Jong, Andrea V.
    Oldenburg, Bas
    de Boer, Nanne
    Lowenberg, Mark
    Srivastava, Nidhi
    Jansen, Jeroen M.
    West, Rachel
    de Vries, Annemarie C.
    Haans, Jeoffrey
    Pierik, Marie
    Hoentjen, Frank
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S884 - S884
  • [39] Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
    Biemans, V.
    van der Woude, J.
    Dijkstra, G.
    van der Meulen-de Jong, A.
    Oldenburg, B.
    de Boer, N.
    Lowenberg, M.
    Srivastava, N.
    Jansen, J.
    West, R.
    de Vries, A.
    Haans, J.
    Pierik, M.
    Hoentjen, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S363 - S364
  • [40] Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study
    Tursi, A.
    Mocci, G.
    Cuomo, A.
    Allegretta, L.
    Aragona, G.
    Colucci, R.
    Della Valle, N.
    Ferronato, A.
    Forti, G.
    Gaiani, F.
    Graziani, M. G.
    Lorenzetti, R.
    Luzza, F.
    Paese, P.
    Penna, A.
    Pica, R.
    Piergallini, S.
    Pranzo, G.
    Rodino, S.
    Scarcelli, A.
    Zampaletta, C.
    Cicerone, C.
    Cocco, A.
    De'Angelis, G.
    Donnarumma, L.
    Franceschi, M.
    Gallina, S.
    Grasso, G.
    Larussa, T.
    Luppino, I
    Faggiani, R.
    Fanigliulo, L.
    Pagnini, C.
    Perazzo, P.
    Sacco, R.
    Sebkova, L.
    Scorza, S.
    Serio, M.
    De Monti, A.
    Picchio, M.
    Elisei, W.
    Maconi, G.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (04) : 2099 - 2108
12345